| Biotech Boom 2.0 - Lou Basenese predicted the 2020 top sector (and was proven right)
- This year, he’s here to tell you it’s going to boom AGAIN
Recommended Link
Biden... Boom? 
If you're rolling the dice on a Biden boom, pay attention... Because new research has come to light. A former advisor to the CIA... and the Pentagon... Has just recently revealed -- on camera -- proof that Joe Biden and Kamala Harris are not equipped for reversing this crisis. Frankly, nobody in Washington is. Because, says this ex-insider, every last one of them is too late. In the fallout ahead, most stocks will collapse... the dollar could fail... But there's one strategy that could rebound, as high as 300% or higher over the next five years. | |
 Lou Basenese
Editor and Founder, Trend Trader Daily
Dear Wall Street Daily Reader, There’s no time to waste, so let’s get right at it today… Longtime readers of mine know I predicted the biotech sector would be the top performer in 2020. Before Covid-19 even hit... And that prediction proved to be right. In spades. For proof, look at the performance of the SPDR S&P Biotech ETF (XBI) versus the rest of the market. Coming off the March lows, it surged more than 125%, almost tripling the rally of the S&P 500 Index. 
Recommended Link
"The 12 Million Mile Battery" 
One of Tesla’s “original seven” employees has beaten his former employer, creating a battery technology so powerful it can send a Tesla across country without charging — four times. It’s capable of charging in eight minutes, not hours. It’s on the cusp of sparking a 20,300% market surge over the next decade. | |
My Biggest Personal Investment for 2021 Of course, I’m not writing to say I told you so. Instead, I’m writing to tell you again: biotech is going to be the top performer in 2021. Why? Because as I’ve shared before, the pandemic brought about a permanent shift in investor sentiment for the sector. It’s now become vital to survival. Literally. And that’s not going to change anytime soon. On a more strategic level, I’ve shared with you the first requirement to be a successful trend trader: You need to follow the “smart money” to identify a burgeoning trend before it’s obvious to the rest of Wall Street and Main Street. Well, we did that with biotech in late 2019. And that brings us to the second requirement: riding the momentum of a trend for as long as it lasts. And when it comes to biotech, there’s no signs of it letting up: The major sector indexes are breaking out to new all-time highs, and big pharma is paying higher and higher triple-digit premiums to acquire upstart biotechs. Bottom line: I already told you to overweight small- and micro caps going into 2021. But if you want to super-charge your profit potential in 2021, you should overweight small biotech stocks. I’m convinced they’re going to repeat their chart-topping performance from 2020. So much so, I’m allocating the largest percentage of my personal portfolio to the sector. You may want to consider doing the same. Ahead of the tape, 
Lou Basenese
Editor and Founder, Trend Trader Daily Louis Basenese is a professional investor, and one of the country’s leading technology analysts. He’s spent the past 20 years analyzing emerging technologies, and developing a proven methodology to consistently profit from them. Lou began his investment career at Morgan Stanley, where he was eventually tasked with directing over $1.5 billion in capital. Based on his proven track record as a financial analyst and investor, Lou became a television commentator on Fox Business and CNBC, and a market expert in the pages of The Wall Street Journal and Business Insider. But ultimately, Lou found he preferred helping Main Street investors like you. By providing ordinary investors with extraordinary research, he discovered that he can help his readers change their financial futures, and change their lives for the better. And that explains why he recently launched Trend Trader Daily. With this new service, Lou can share his research with you on groundbreaking new technologies and emerging sectors — well before he shares this information with the general public on TV, the internet, or anywhere else. | 
© 2021 Paradigm Press, LLC. 808 Saint Paul Street, Baltimore MD 21202. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. 
No comments:
Post a Comment